Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium-Reference-Cited by-同舟云学术

Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium

Published:2023-07-20 Issue:21 Volume:41 Page:3712-3723
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

El Zarif Talal¹^ORCID,Nassar Amin H.²^ORCID,Adib Elio¹³,Fitzgerald Bailey G.⁴^ORCID,Huang Jiaming¹^ORCID,Mouhieddine Tarek H.⁴^ORCID,Rubinstein Paul G.⁵^ORCID,Nonato Taylor⁶,McKay Rana R.⁶^ORCID,Li Mingjia⁷^ORCID,Mittra Arjun⁷^ORCID,Owen Dwight H.⁷^ORCID,Baiocchi Robert A.⁸,Lorentsen Michael⁹^ORCID,Dittus Christopher⁹^ORCID,Dizman Nazli²^ORCID,Falohun Adewunmi¹⁰,Abdel-Wahab Noha¹⁰¹¹^ORCID,Diab Adi¹⁰^ORCID,Bankapur Anand¹²,Reed Alexandra¹²,Kim Chul¹³^ORCID,Arora Aakriti¹⁴,Shah Neil J.¹⁵^ORCID,El-Am Edward¹⁶,Kozaily Elie¹⁶^ORCID,Abdallah Wassim¹⁷^ORCID,Al-Hader Ahmad¹⁶,Abu Ghazal Batool¹⁸,Saeed Anwaar¹⁸¹⁹^ORCID,Drolen Claire²⁰^ORCID,Lechner Melissa G.²⁰^ORCID,Drakaki Alexandra²⁰^ORCID,Baena Javier²¹,Nebhan Caroline A.²²^ORCID,Haykal Tarek²³^ORCID,Morse Michael A.²³,Cortellini Alessio²⁴²⁵^ORCID,Pinato David J.²⁴²⁶^ORCID,Dalla Pria Alessia²⁴²⁷^ORCID,Hall Evan²⁸^ORCID,Bakalov Veli²⁹,Bahary Nathan²⁹^ORCID,Rajkumar Aarthi³⁰,Mangla Ankit³⁰^ORCID,Shah Vishal³¹^ORCID,Singh Parminder³¹,Aboubakar Nana Frank³²^ORCID,Lopetegui-Lia Nerea³³^ORCID,Dima Danai³³^ORCID,Dobbs Ryan W.⁵^ORCID,Funchain Pauline³³^ORCID,Saleem Rabia³⁴,Woodford Rachel³⁵^ORCID,Long Georgina V.³⁶^ORCID,Menzies Alexander M.³⁵^ORCID,Genova Carlo³⁷³⁸^ORCID,Barletta Giulia³⁹,Puri Sonam⁴⁰^ORCID,Florou Vaia⁴⁰^ORCID,Idossa Dame⁴¹,Saponara Maristella⁴²,Queirolo Paola⁴²,Lamberti Giuseppe⁴³^ORCID,Addeo Alfredo⁴⁴^ORCID,Bersanelli Melissa⁴⁵^ORCID,Freeman Dory¹,Xie Wanling¹^ORCID,Reid Erin G.⁶^ORCID,Chiao Elizabeth Y.¹⁰^ORCID,Sharon Elad⁴⁶^ORCID,Johnson Douglas B.²²^ORCID,Ramaswami Ramya⁴⁷^ORCID,Bower Mark²⁴²⁷^ORCID,Emu Brinda²,Marron Thomas U.⁴,Choueiri Toni K.¹^ORCID,Baden Lindsey R.³,Lurain Kathryn⁴⁷^ORCID,Sonpavde Guru P.⁴⁸^ORCID,Naqash Abdul Rafeh³⁴^ORCID

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA

2. Yale University School of Medicine, New Haven, CT

3. Brigham and Women's Hospital, Boston, MA

4. Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

5. Division of Hematology/Oncology, Ruth M. Rothstein CORE Center, Cook County Health and Hospital Systems (Cook County Hospital), University of Illinois Chicago Cancer Center, Chicago, IL

6. Moores Cancer Center, The University of California San Diego, La Jolla, CA

7. Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

8. Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH

9. Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, NC

10. University of Texas MD Anderson Cancer Center, Houston, TX

11. Assiut University Faculty of Medicine, Assiut University Hospitals, Assiut, Egypt

12. Department of Surgery, Division of Urology, Cook County Health, Chicago, IL

13. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

14. Medstar/Georgetown-Washington Hospital Center, Washington, DC

15. Memorial Sloan Kettering Cancer Center, New York, NY

16. Indiana University School of Medicine, Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

17. Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA

18. Kansas University Cancer Center, Kansas City, KS

19. University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA

20. University of California Los Angeles, Los Angeles, CA

21. 12 de Octubre University Hospital, Madrid, Spain

22. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

23. Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC

24. Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom

25. Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy

26. Department of Translational Medicine, Università Del Piemonte Orientale “A. Avogadro”, Novara, Italy

27. Chelsea and Westminster Hospital, London, United Kingdom

28. University of Washington, Seattle, WA

29. Allegheny Health Network, Pittsburgh, PA

30. Seidman Cancer Center, University Hospitals, Cleveland, OH

31. Mayo Clinic, Phoenix, AZ

32. Université Catholique de Louvain (UCLouvain), Brussels, Belgium

33. Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

34. Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK

35. Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia

36. Melanoma Institute Australia, Faculty of Medicine & Health, Charles Perkins Centre, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, NSW, Australia

37. UO Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy

38. Dipartimento di Medicina Interna e Specialità Mediche (DiMI), Università degli Studi di Genova, Genova, Italy

39. UO Oncologia Medica 2, IRCCS Ospedale Policlinico San Martino, Genova, Italy

40. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

41. University of California San Francisco, San Francisco, CA

42. Division of Melanoma and Sarcoma Medical Treatment, IEO European Institute of Oncology IRCCS Milan, Milan, Italy

43. Department of Experimental, Diagnostic and Specialty Medicine, Università di Bologna, Bologna, Italy

44. Swiss Cancer Center Leman, Geneva University Hospitals, University of Geneva, Geneva, Switzerland

45. University Hospital of Parma, Parma, Italy

46. Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD

47. HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

48. AdventHealth Cancer Institute, Orlando, FL

Abstract

PURPOSE Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. METHODS This retrospective study included PWH treated with anti–PD-1- or anti–PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). RESULTS Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti–PD-1/anti–PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load <400 copies/mL. Twenty percent (79/390) had any grade immune-related adverse events (irAEs) and 7.7% (30/390) had grade ≥3 irAEs. ORRs were 69% (nonmelanoma skin cancer), 31% (NSCLC), 16% (HCC), and 11% (HNSCC). In the matched mNSCLC cohort (61 PWH v 110 PWOH), 20% (12/61) PWH and 22% (24/110) PWOH had irAEs. Adjusted 42-month RMST difference was –0.06 months (95% CI, –5.49 to 5.37; P = .98) for PFS and 2.23 months (95% CI, –4.02 to 8.48; P = .48) for OS. CONCLUSION Among PWH, ICIs demonstrated differential activity across cancer types with no excess toxicity. Safety and activity of ICIs were similar between matched cohorts of PWH and PWOH with mNSCLC.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.02459

Reference40 articles.

1. Combining cancer immunotherapy and targeted therapy

2. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

3. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

4. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

5. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Missed Opportunity: HIV, Hepatitis C Virus (HCV), and Hepatitis B Virus (HBV) Positive Patients in Neoadjuvant and Perioperative Immunotherapy Clinical Trials for Lung Cancer;Cureus;2023-12-29

2. Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective;Cancers;2023-12-24

3. Immune checkpoint inhibitors as potential therapy for reverting T-cell exhaustion and reverting HIV latency in people living with HIV;Frontiers in Immunology;2023-12-07

4. HIV Associated Lung Cancer: Unique Clinicopathologic Features and Immune Biomarkers Impacting Lung Cancer Screening and Management;Clinical Lung Cancer;2023-12

5. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy;BJU International;2023-09-05